BioWorld Asia

Jan. 11, 2006

Symphogen Gets $25M, As Antibody Products Progress

Symphogen A/S raised $25 million in a Series D funding that attracted one new investor. (BioWorld International) Read More

GW Pharma Bringing Cannabis Drug To U.S. For Phase III Work

Seoul University Confirms Stem Cell Work As Fraud

Finnish Institute Gets EUR3M For GMP-Grade Stem Cells

Avidex Gets £5M From Syngenta; Firms Agree To Work On Allergy

Industry Sees Risks In New European Regulatory Tools

LibraGen Initiates Agreement With Pierre Fabre Médicament

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...